Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Septic shock is a major cause of death worldwide and a considerable healthcare burden in the twenty-first century. Attention has shifted from damaging effects of the proinflammatory response to the detrimental role of antiinflammation, a phenomenon known as sepsis-induced immunoparalysis. Sepsis-induced immunoparalysis may render patients vulnerable to secondary infections and is associated with impaired outcome. The immunoparalysis hypothesis compels us to reevaluate the current management of septic shock and to assess whether we are inadvertently compromising or altering the host immune response. In this perspective, we discuss the potential detrimental role of norepinephrine, the cornerstone treatment for septic shock, in sepsis-induced immunoparalysis. We provide a short overview of the current understanding of the immunologic pathophysiology of sepsis, followed by a detailed description of the immunomodulatory effects of norepinephrine and alternative vasopressors. We conclude that although the development of novel therapies aimed at reversing immunoparalysis is underway, the use of norepinephrine may aggravate the development, extent, and duration of sepsis-induced immunoparalysis. Current in vitro and animal data indicate that norepinephrine treatment exerts immunosuppressive and bacterial growth-promoting effects and may increase susceptibility toward infections. However, evidence in humans is circumstantial, as immunologic effects of norepinephrine have not been investigated properly in experimental or clinical studies. Alternatives such as vasopressin/selepressin, angiotensin II, and phenylephrine could have a fundamental advantage over norepinephrine with respect to their immunologic properties. However, also for these agents, in vivo immunologic data in humans are largely lacking. As such, human studies on the immunomodulatory properties of norepinephrine and viable alternatives are highly warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548
Self-citationComparison of Dopamine and Norepinephrine in the Treatment of Shock
De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907118 · Cited by 1,940 · cited 3×
“significantly decreased mortality was only found in a subgroup of cardiogenic shock patients (44).”
InfluentialVasopressin versus Norepinephrine Infusion in Patients with Septic Shock
Russell, J. A., Walley, K. R., Singer, J., Gordon, A. C., Hébert, P. C., Cooper, D. J., Holmes, C. L., Mehta, S., Granton, J. T., Storms, M. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa067373 · Cited by 1,924
Vasopressors for the treatment of septic shock: Systematic review and meta-analysis.
Avni, T., Lador, A., Lev, S., Leibovici, L., Paul, M., & Grossman, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129305 · Cited by 293 · cited 1×
“In addition, a recent meta-analysis failed to show a survival benefit for norepinephrine over phenylephrine (56).”
Kox, M., van Eijk, L. T., Zwaag, J., van den Wildenberg, J., Sweep, F. C. G. J., van der Hoeven, J. G., & Pickkers, P. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322174111 · Cited by 268
Self-citationIntravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
Chawla, L. S., Busse, L., Brasha-Mitchell, E., Davison, D., Honiq, J., Alotaibi, Z., & Seneff, M. G. (2014) · Critical Care · doi:10.1186/s13054-014-0534-9 · Cited by 197 · cited 1×
“In a pilot study in patients with high-output shock, angiotensin II was well-tolerated and markedly reduced norepinephrine requirement, albeit with considerable interindividual variation (54).”
Cited by
Advances in the understanding and treatment of sepsis-induced immunosuppression
Venet, F., & Monneret, G. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.165 · Cited by 981
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock
Marik, P. E., Khangoora, V., Rivera, R., Hooper, M. H., & Catravas, J. (2017) · Chest · doi:10.1016/j.chest.2016.11.036 · Cited by 887
Sepsis-Induced Immunosuppression
Torres, L. K., Pickkers, P., & van der Poll, T. (2022) · Annual Review of Physiology · doi:10.1146/annurev-physiol-061121-040214 · Cited by 355
Self-citationThe β2-adrenergic receptor controls inflammation by driving rapid IL-10 secretion
Ağaç, D., Estrada, L. D., Maples, R., Hooper, L. V., & Farrar, J. D. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.09.004 · Cited by 200
Russell, J. A., Vincent, J.-L., Kjølbye, A. L., Olsson, H., Blemings, A., Spapen, H., Carl, P., Laterre, P.-F., & Grundemar, L. (2017) · Critical Care · doi:10.1186/s13054-017-1798-7 · Cited by 103
Metadata
- Authors
- Stolk, R. F., van der Poll, T., Angus, D. C., van der Hoeven, J. G., Pickkers, P., & Kox, M.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09-01
- Volume
- 194
- Issue
- 5
- Pages
- 550-558
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2461553457
- Cited by
- 148
- References
- 6
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis. https://app.cochat.ai/papers/10.1164/rccm.201604-0862cp
- The paper
- Stolk, R. F., van der Poll, T., Angus, D. C., van der Hoeven, J. G., Pickkers, P., & Kox, M. (2016). Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201604-0862cp
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.